Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer (S1216)

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2016 by Southwest Oncology Group
Millennium Pharmaceuticals, Inc.
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Southwest Oncology Group Identifier:
First received: March 8, 2013
Last updated: October 4, 2016
Last verified: October 2016
No Study Results Posted on for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: July 2020 (Final data collection date for primary outcome measure)